Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Retained Earnings (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Retained Earnings for 15 consecutive years, with -$342.2 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 7.69% to -$342.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$342.2 million through Dec 2025, down 7.69% year-over-year, with the annual reading at -$333.5 million for FY2025, 4.24% down from the prior year.
  • Retained Earnings for Q4 2025 was -$342.2 million at Aytu Biopharma, down from -$331.6 million in the prior quarter.
  • The five-year high for Retained Earnings was -$178.3 million in Q2 2021, with the low at -$342.2 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$292.9 million, with a median of -$312.2 million recorded in 2023.
  • The sharpest move saw Retained Earnings tumbled 65.87% in 2021, then increased 0.52% in 2025.
  • Over 5 years, Retained Earnings stood at -$217.7 million in 2021, then plummeted by 35.27% to -$294.5 million in 2022, then dropped by 6.11% to -$312.5 million in 2023, then decreased by 1.68% to -$317.7 million in 2024, then fell by 7.69% to -$342.2 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$342.2 million, -$331.6 million, and -$333.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.